Evaluation and Management of Patients with Chronic Thromboembolic Pulmonary Hypertension - Consensus Statement from ISHLT

Published 2 August 2021

Marc de Perrot, MD; Deepa Gopalan, MD; David Jenkins, MD; Irene M. Lang, MD; Elie Fadel, MD; Marion Delcroix, MD; Raymond Benza, MD; Gustavo A. Heresi, MD; Manreet Kanwar, MD; John T. Granton, MD; Micheal McInnis, MD; Frederikus A. Klok, MD; Kim M. Kerr, MD; Joanna Pepke-Zaba, MD; Mark Toshner, MD; Anastasia Bykova, RN, NP; Andrea M. D’Armini, MD; Ivan M. Robbins, MD; Michael Madani, MD; David McGiffin, MD; Christoph B. Wiedenroth, MD; Sebastian Mafeld, MD; Isabelle Opitz, MD; Olaf Mercier, MD; Patricia A. Uber, PharmD; Robert P. Frantz, MD

J Heart Lung Transplant. 2021 Nov; 40(11):1301-1326.

• Anesthesiology & Critical Care
• Cardiology
• Consensus Document
• Nursing & Allied Health
• Pathology
• Pharmacy
• Publications & Journals
• Pulmonary Vascular Disease (PAH & CTEPH)
• Pulmonology
• Research & Immunology
• Standards & Guidelines

Chronic thromboembolic pulmonary hypertension (CTEPH) is a distinct pulmonary vascular disease classified as group 4 in the classification of pulmonary hypertension. It is characterized by chronic stenosis and occlusion of the pulmonary arteries due to obstructive intraluminal organized thromboembolic material.

ISHLT members have recognized the importance of a consensus statement on the evaluation and management of patients with chronic thromboembolic pulmonary hypertension. Each working group for this project provided a separate section based on an extensive literature search, which were then coalesced into a single document. Due to the limited number of comparative trials in this field, the document was written as a literature review with expert opinion rather than based on level of evidence.

Read at JHLT

Download Figures